NPI: 1285685727 · CLINTWOOD, VA 24228 · Critical Access Hospital · NPI assigned 05/12/2006
Authorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
| Authorized Official | HILTON, SHANE (EVP/CFO) |
| NPI Enumeration Date | 05/12/2006 |
Other providers sharing the same authorized official: HILTON, SHANE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,051 | $384K |
| 2019 | 22,437 | $662K |
| 2020 | 18,098 | $862K |
| 2021 | 20,177 | $1.06M |
| 2022 | 22,334 | $1.28M |
| 2023 | 25,256 | $1.63M |
| 2024 | 16,031 | $1.06M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,992 | 7,915 | $2.09M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 6,847 | 6,086 | $1.16M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,280 | 3,709 | $890K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,073 | 1,758 | $872K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3,399 | 3,100 | $282K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1,451 | 1,319 | $225K |
| 70450 | Computed tomography, head or brain; without contrast material | 826 | 758 | $223K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,206 | 1,108 | $206K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1,519 | 1,341 | $175K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 449 | 415 | $121K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,284 | 1,128 | $104K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 276 | 252 | $76K |
| 80053 | Comprehensive metabolic panel | 11,047 | 9,136 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 607 | 547 | $46K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 258 | 233 | $40K |
| 71046 | Radiologic examination, chest; 2 views | 2,943 | 2,657 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 107 | 79 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 750 | 611 | $35K |
| 36415 | Collection of venous blood by venipuncture | 7,052 | 5,847 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | 3,290 | 2,989 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 896 | 835 | $19K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 195 | 164 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11,744 | 9,424 | $16K |
| 80061 | Lipid panel | 2,316 | 2,152 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,810 | 3,701 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,382 | 2,045 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,844 | 1,721 | $10K |
| 87040 | 1,421 | 709 | $9K | |
| 72100 | 299 | 285 | $8K | |
| 83880 | 748 | 652 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 490 | 426 | $7K |
| 84484 | 3,962 | 2,693 | $5K | |
| 85027 | 1,259 | 1,125 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3,495 | 3,069 | $5K |
| 81001 | 4,720 | 4,093 | $4K | |
| 84439 | 577 | 537 | $4K | |
| 82607 | 641 | 591 | $4K | |
| 87077 | 1,585 | 1,442 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,005 | 1,377 | $3K |
| 73562 | 117 | 99 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,110 | 3,553 | $3K |
| 71045 | Radiologic examination, chest; single view | 2,212 | 1,886 | $2K |
| J3490 | Unclassified drugs | 704 | 563 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 866 | 749 | $2K |
| 83605 | 2,313 | 1,710 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,861 | 1,702 | $2K |
| 74018 | 85 | 82 | $2K | |
| 80306 | 720 | 632 | $2K | |
| 81003 | 2,313 | 2,095 | $2K | |
| 80329 | 84 | 37 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 117 | 109 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 28 | 26 | $1K |
| 87088 | 782 | 689 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,501 | 2,221 | $1K |
| 73610 | 77 | 68 | $873.86 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,682 | 2,236 | $850.74 |
| 81025 | 1,671 | 1,502 | $840.83 | |
| 85610 | 912 | 664 | $832.62 | |
| 73630 | 29 | 27 | $783.04 | |
| 83735 | 1,217 | 1,040 | $703.98 | |
| 85379 | 288 | 256 | $641.39 | |
| 80320 | 176 | 153 | $564.41 | |
| 80143 | 128 | 110 | $548.08 | |
| 99406 | 14 | 13 | $517.82 | |
| 83690 | 1,755 | 1,542 | $513.52 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 30 | 26 | $451.94 |
| 90715 | 14 | 12 | $448.41 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20 | 20 | $413.94 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 67 | 60 | $380.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,924 | 1,610 | $366.78 |
| 80179 | 130 | 110 | $325.63 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,217 | 1,140 | $323.41 |
| 87186 | 519 | 460 | $280.26 | |
| 80076 | 127 | 121 | $277.16 | |
| 96376 | 366 | 270 | $234.60 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 28 | 24 | $220.96 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,109 | 971 | $161.88 |
| 82140 | 57 | 50 | $141.86 | |
| 87081 | 661 | 599 | $101.78 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 742 | 670 | $99.44 |
| 94761 | 417 | 326 | $76.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 545 | 501 | $74.97 |
| J7030 | Infusion, normal saline solution , 1000 cc | 483 | 396 | $58.36 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 15 | 12 | $51.31 |
| 82150 | 29 | 25 | $37.38 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 391 | 341 | $30.64 |
| 85730 | 106 | 93 | $27.28 | |
| 82043 | 12 | 12 | $21.90 | |
| 87070 | 15 | 13 | $21.00 | |
| 82248 | 17 | 15 | $20.82 | |
| 82570 | 12 | 12 | $17.17 | |
| 84100 | 77 | 63 | $12.43 | |
| 87205 | 15 | 13 | $10.48 | |
| 87807 | 99 | 95 | $8.19 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 193 | 128 | $6.54 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 30 | 24 | $3.33 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 14 | 12 | $0.43 |
| 82803 | 15 | 12 | $0.00 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 51 | 48 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 13 | 13 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 17 | 17 | $0.00 |